Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT‐2 framework-Reference-Cited by-同舟云学术

Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT‐2 framework

Published:2022-12-27 Issue:1 Volume:95 Page:
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:Journal of Medical Virology

Author:

Dhillon Sharonjit K.¹,Cocuzza Clementina E.²^ORCID,Chung Pui Yan Jenny¹,Martinelli Marianna²,Giubbi Chiara²,Njoku Ruth C.²,Bhatia Ramya³⁴^ORCID,Cuschieri Kate³⁴,Arbyn Marc¹⁵

Affiliation:

1. Unit of Cancer Epidemiology/Belgian Cancer Centre Scientific Institute of Public Health Brussels Belgium

2. Laboratory of Clinical Microbiology and Virology, Department of Medicine and Surgery University of Milano–Bicocca Monza Italy

3. Scottish HPV Reference Laboratory Royal Infirmary of Edinburgh Edinburgh Scotland UK

4. HPV Research Group, Centre for Reproductive Health University of Edinburgh Edinburgh Scotland UK

5. Department of Human Structure and Repair, Faculty of Medicine and Health Sciences University Ghent Ghent Belgium

Funder

European Commission

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.28417

Reference31 articles.

1. International Agency forResearch on Cancer.Cervical Cancer Screening. IARC Handbooks of Cancer Prevention. Vol18.IARC Publications.https://publications.iarc.fr/604

2. Histology of cervical intraepithelial neoplasia and the role of biomarkers

3. International Agency for Research on Cancer.Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 90. Vol90.IARC Press;2007.

4. A review of human carcinogens—Part B: biological agents

5. Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer